ReviewThe Journal of clinical endocrinology and metabolism2021
Evaluation and Treatment of Amiodarone-Induced Thyroid Disorders.
Review in The Journal of clinical endocrinology and metabolism, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 59 citations in OpenAlex.
- Guideline
- 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.Journal of the American College of Cardiology · 2024Guideline
- Refractory amiodarone-induced thyrotoxicosis causing malignant arrhythmias, treated with therapeutic plasma exchange-bridged thyroidectomy.BMJ case reports · 2026Article
- Biphasic Amiodarone-Induced Thyroid Dysfunction: De Novo Hypothyroidism Followed by Delayed Type 2 Thyrotoxicosis: A Case Report.The Permanente journal · 2026Article
- Amiodarone- and Lithium-Induced Thyroid Dysfunction-Prescriber Specialties Involved in Potential Prescribing Cascades: A Retrospective Study.Health science reports · 2026Article
- Identification of pharmaceuticals and environmental contaminants as obesogens inducing a locomotion-independent thrifty phenotype.Communications biology · 2026Article
- Imaging evaluation of amiodarone-induced thyroid dysfunction: ultrasonographic and radionuclide findings with clinical correlation.Quantitative imaging in medicine and surgery · 2025Article
- Measurement of Amiodarone Levels in the Breast Milk of a Japanese Woman With Peripartum Cardiomyopathy.Cureus · 2025Article
- Disproportionality analysis and risk factor assessment of drug-associated thyroid dysfunction adverse events: a study based on the FAERS database.Endocrine connections · 2025Article
- Incidence and Risk Factors for Amiodarone-Induced Thyroid Dysfunction: A Nationwide Retrospective Cohort Study.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2025Article
- Amiodarone Advances the Apoptosis of Cardiomyocytes by Repressing Sigmar1 Expression and Blocking KCNH2-related Potassium Channels.Current molecular medicine · 2025Article
- Amiodarone Therapy: Updated Practical Insights.Journal of clinical medicine · 2024Review
- Enhanced Differentiation of Amiodarone-Induced Thyrotoxicosis Types Using Semi-Quantitative 99mTc-MIBI Uptake Analysis: A Pilot Study.Medical science monitor : international medical journal of experimental and clinical research · 2024Article
- The global prevalence of sexual dysfunction in men with thyroid gland disorders: a systematic review and meta-analysis.Journal of diabetes and metabolic disorders · 2024Review
- The Utility of Intravenous Methylprednisolone as an Adjunct Treatment for Drug-Resistant Amiodarone-Induced Thyrotoxicosis.Journal of clinical medicine · 2024Article
- Adverse drug reaction signals mining comparison of amiodarone and dronedarone: a pharmacovigilance study based on FAERS.Frontiers in pharmacology · 2024Article
- Review
- [Type 2 amiodarone-induced thyrotoxicosis: prevalence, time and predictors of development].Problemy endokrinologii · 2023Article
- Development and Validation of a Prediction Model for Incident Hypothyroidism in a National Chronic Kidney Disease Cohort.The Journal of clinical endocrinology and metabolism · 2023Article
- A Brief Look at Hashimoto's Disease, Adrenal Incidentalomas, Obesity and Insulin Resistance-Could Endocrine Disruptors Be the Other Side of the Same Coin?Medicina (Kaunas, Lithuania) · 2023Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Amiodarone is a class III antiarrhythmic drug containing 37% iodine by weight, with a structure similar to that of thyroid hormones. Deiodination of amiodarone releases large amounts of iodine that can impair thyroid function, causing either hypothyroidism or thyrotoxicosis in susceptible individuals reflecting ~20% of patients administered the drug. Not only the excess iodine, but also the amiodarone (or its metabolite, desethylamiodarone) itself may cause thyroid dysfunction by direct cytotoxicity on thyroid cells. We present an overview of the epidemiology and pathophysiology of amiodarone-induced thyroid disorders, with a focus on the various forms of clinical presentation and recommendations for personalized management of each form.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.